EXEL Stock Overview
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Exelixis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.87 |
| 52 Week High | US$24.34 |
| 52 Week Low | US$18.08 |
| Beta | 0.57 |
| 1 Month Change | -3.83% |
| 3 Month Change | 3.44% |
| 1 Year Change | 21.33% |
| 3 Year Change | -7.15% |
| 5 Year Change | 16.33% |
| Change since IPO | 50.58% |
Recent News & Updates
Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors
Apr 22
Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024
Mar 28Recent updates
Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors
Apr 22Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024
Mar 28We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease
Feb 26Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles
Jan 17Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors
Dec 27An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued
May 30Exelixis initiated at outperform at JMP Securities on cash flow, Cabometyx franchise
Oct 18Exelixis: Efforts Continue To Diversify The Pipeline
Sep 15Exelixis, Teva fight over Cabometyx generic again
Sep 06Exelixis Needs To Move Away From Its Overdependence On Cabozantinib
Aug 03Exelixis again sues MSN Pharmaceuticals over Cabometyx generic
Jul 19Exelixis to pay Ryvu $3M upfront in license deal to develop targeted cancer drugs
Jul 07Exelixis: Becoming A Giant Pharma
May 18Exelixis: Beyond The Cabozantinib Franchise
Apr 21Shareholder Returns
| EXEL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | -2.5% | -3.2% |
| 1Y | 21.3% | -3.7% | 19.3% |
Return vs Industry: EXEL exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: EXEL exceeded the US Market which returned 19.3% over the past year.
Price Volatility
| EXEL volatility | |
|---|---|
| EXEL Average Weekly Movement | 3.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EXEL has not had significant price volatility in the past 3 months.
Volatility Over Time: EXEL's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 1,310 | Mike Morrissey | www.exelixis.com |
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
Exelixis, Inc. Fundamentals Summary
| EXEL fundamental statistics | |
|---|---|
| Market cap | US$6.74b |
| Earnings (TTM) | US$207.77m |
| Revenue (TTM) | US$1.83b |
32.5x
P/E Ratio3.7x
P/S RatioIs EXEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXEL income statement (TTM) | |
|---|---|
| Revenue | US$1.83b |
| Cost of Revenue | US$72.55m |
| Gross Profit | US$1.76b |
| Other Expenses | US$1.55b |
| Earnings | US$207.77m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 0.70 |
| Gross Margin | 96.04% |
| Net Profit Margin | 11.35% |
| Debt/Equity Ratio | 0% |
How did EXEL perform over the long term?
See historical performance and comparison